Edition:
India

Amgen Says Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia


Saturday, 29 Aug 2020 

Aug 29 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES POSITIVE DATA FROM PHASE 3B STUDY OF REPATHA® (EVOLOCUMAB) IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AT ESC CONGRESS 2020.AMGEN INC - FIRST PHASE 3 TRIAL EVALUATING A PCSK9 INHIBITOR WHEN ADDED TO LIPID-LOWERING THERAPY IN PEDIATRIC HEFH POPULAT.AMGEN INC - REPATHA SIGNIFICANTLY REDUCED LDL-C AND IMPROVED ALL SECONDARY LIPID PARAMETERS.AMGEN INC - NO NEW SAFETY RISKS WERE IDENTIFIED.AMGEN -STUDY SHOW IN PEDIATRIC PATIENTS WITH HEFH, MONTHLY TREATMENT WITH REPATHA REDUCED LDL-C BY MEAN 38.3% FROM BASELINE COMPARED TO PLACEBO.